A securities fraud class action has been filed against Insulet Corporation and certain senior executives, with a lead plaintiff deadline of August 31, 2026. The lawsuit, pending in the U.S. District Court for the District of Massachusetts, alleges that Insulet misrepresented the safety of its Omnipod insulin delivery products and its manufacturing quality. On March 12, 2026, the company disclosed a manufacturing defect causing insulin under-delivery, triggering a 6.88% stock drop from $236.07 to $219.84 per share. A second correction on May 26, 2026, covering Omnipod 5, Omnipod DASH, and Omnipod Eros systems, led to a further 5.07% decline from $218.11 to $146.01 per share. Investors who suffered losses are encouraged to contact Bleichmar Fonti & Auld LLP before the deadline to seek lead plaintiff appointment.
Insulet CorporationSecurities fraud class action lawsuit alleging misrepresentation of Omnipod safety and manufacturing quality, with stock drops on disclosures.